FDA Grants SPA for Puma's PB272 Breast Cancer Trial

Puma Biotechnology Inc. said its Phase III trial of PB272 (neratinib) will be conducted under a special protocol assessment from the FDA, providing specific guidance for design, endpoints and statistical analysis in the trial.